July 20, 2022
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides’ Pepaxto
Media
July 15, 2022
BONESUPPORT HOLDING AB (PUBL) – PUBLISHES Q2 2022 INTERIM REPORT
July 15, 2022
Oncopeptides has carried out a directed share issue of approximately SEK 435.6 million (approximately USD 41.1 million)
July 14, 2022
Hemab Therapeutics Presents New Data on HMB-001 for the Treatment of Glanzmann Thrombasthenia and Other Bleeding Disorders at 2022 ISTH Congress
July 07, 2022
BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim Report Q2 2022
July 07, 2022
Ariceum Therapeutics Appoints Chief Business Officer
July 05, 2022
Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma
June 28, 2022
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
June 23, 2022
CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU for patients with triple class refractory multiple myeloma
June 23, 2022
Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-2059, An Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1
